FSIP1 and Alzheimer disease: While most prior studies focused primarily on AG18051 [38], this study represents the first comparative cellular characterization of both inhibitors and their potential to reduce HSD10-driven pathology, offering new insights into the therapeutic application of HSD10 inhibition in AD treatment.